Formulation and characterisation of solid lipid nanoparticle hydrogels of Naproxen
Keywords:
Naproxen, Solid lipid nanoparticles, Bioavailability, Span 80, Tween 80Abstract
Naproxen is Non-steroidal anti-inflammatory drug (NSAID) and is considered to be first line drug in treatment of rheumatoid arthritis, osteo arthritis and ankylosing spondylitis. Naproxen undergoes first pass metabolism when taken orally and it also produces some GI problems. The aim of the study is to improve the efficacy, drug loading capacity and biocompatibility of drug by formulating in solid lipid nanoparticles. To minimize the toxicity and increase the stability of drug by encapsulating in nanoparticulate system. To optimize the developed solid lipid nanoparticle formulations. Drug Naproxen has been loaded with lipid carriers and then formulated in to Hydrogels with the objective of prolonging its action and avoiding its most side effects by incorporation of solid lipid carriers which is achieved by Nanostructured lipid carrier (NLC). Methods: Nanostructured lipid carrier was prepared by Ultra sonication or High-Speed Homogenization method. Characterization of nanostructured lipid carrier was performed by measuring particle size, drug entrapment efficiency and in-vitro drug release. Spherical uniform particles (size below 500 nm), Drug entrapment efficiency was found to be in the range of about 69-86%. The drug release profile of all the formulations after 24 h study was found to be in the range of 43%- 94%. Formulation showing sustained release profile at the end of the study was found to be the best formulation. Optimized formulation was converted in to hydrogel with Carbopol as gelling agent was formulated and characterized for its physical appearance, pH, viscosity, spreadability, homogeneity studies. Conclusion: The result concludes that Naproxen loaded nanostructured lipid carrier could be a potential drug delivery system.
Downloads
References
Shekelle PG, Newberry SJ, FitzGerald JD, Motala A, O'Hanlon CE, Tariq A, Okunogbe A, Han D, Shanman R. Management of Gout: A Systematic Review in Support of an American College of Physicians Clinical Practice Guideline. Ann Intern Med. 2017 Jan 03;166(1):37-51.
Phillips WJ, Currier BL. Analgesic pharmacology: II. Specific analgesics. J Am Acad Orthop Surg. 2004 Jul-Aug;12(4):221-33.
Dawood MY. Primary dysmenorrhea: advances in pathogenesis and management. Obstet Gynecol. 2006 Aug;108(2):428-41.
Oyler DR, Parli SE, Bernard AC, Chang PK, Procter LD, Harned ME. Nonopioid management of acute pain associated with trauma: Focus on pharmacologic options. J Trauma Acute Care Surg. 2015 Sep;79(3):475-83.
Zacher J, Altman R, Bellamy N, Brühlmann P, Da Silva J, Huskisson E, Taylor RS. Topical diclofenac and its role in pain and inflammation: an evidence-based review. Curr Med Res Opin. 2008 Apr;24(4):925-50.
van den Bekerom MPJ, Sjer A, Somford MP, Bulstra GH, Struijs PAA, Kerkhoffs GMMJ. Non-steroidal anti-inflammatory drugs (NSAIDs) for treating acute ankle sprains in adults: benefits outweigh adverse events. Knee Surg Sports Traumatol Arthrosc. 2015 Aug;23(8):2390-2399.
May JJ, Lovell G, Hopkins WG. Effectiveness of 1% diclofenac gel in the treatment of wrist extensor tenosynovitis in long distance kayakers. J Sci Med Sport. 2007 Feb;10(1):59-65.
Barkin RL. Topical Nonsteroidal Anti-Inflammatory Drugs: The Importance of Drug, Delivery, and Therapeutic Outcome. Am J Ther. 2015 Sep-Oct;22(5):388-407.
Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971 Jun 23;231(25):232-5.
Chaiamnuay S, Allison JJ, Curtis JR. Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs. Am J Health Syst Pharm. 2006 Oct 01;63(19):1837-51.
Scott LJ. Intravenous ibuprofen: in adults for pain and fever. Drugs. 2012 May 28;72(8):1099-109.
Sostres C, Gargallo CJ, Arroyo MT, Lanas A. Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol. 2010 Apr;24(2):121-32.
Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med. 1999 May 31;106(5B):13S-24S.
Harirforoosh S, Asghar W, Jamali F. Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. J Pharm Pharm Sci. 2013;16(5):821-47.
Sriuttha P, Sirichanchuen B, Permsuwan U. Hepatotoxicity of Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review of Randomized Controlled Trials. Int J Hepatol. 2018; 2018:5253623.
Schafer AI. Effects of nonsteroidal anti-inflammatory therapy on platelets. Am J Med. 1999 May 31;106(5B):25S-36S.
Berkes EA. Anaphylactic and anaphylactoid reactions to aspirin and other NSAIDs. Clin Rev Allergy Immunol. 2003 Apr;24(2):137-48.
Szczeklik A. Adverse reactions to aspirin and nonsteroidal anti-inflammatory drugs. Ann Allergy. 1987 Nov;59(5 Pt 2):113-8.
Rothenberg RJ, Holcomb JP. Guidelines for Monitoring of NSAIDS: Who Listened? J Clin Rheumatol. 2000 Oct;6(5):258-65.
Hunter LJ, Wood DM, Dargan PI. The patterns of toxicity and management of acute nonsteroidal anti-inflammatory drug (NSAID) overdose. Open Access Emerg Med. 2011; 3:39-48.
Lima TAMd, Furini AAdC, Atique TSC, Di Done P, Machado RLD, Godoy MFd. Analysis of potential drug interactions and adverse reactions to nonsteroidal anti-inflammatory drugs among the elderly. Revista Brasileira de Geriatria e Gerontologia. 2016; 19:533–44.
Abdulla A, Adams N, Bone M, Elliott AM, Gaffin J, Jones D, et al. (2013). Guidance on the management of pain in older people. Age Ageing, 42 Suppl 1: i1–-57.
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
License Terms
This is an open-access article published in the International Journal of Research in Pharmaceutical Sciences and Technology (IJRPST) by Rubatosis Publications.
It is distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, reproduction, and adaptation in any medium or format, provided the original author(s) and source are appropriately credited, a link to the license is provided, and any changes made are indicated.
To view a copy of this license, visit: https://creativecommons.org/licenses/by/4.0/
For any further queries or permissions beyond the scope of this license, please contact: editor@rubatosis.org
